Gujarat Themis Biosyn Amends Preferential Issue to Raise Rs 335 Crore
Gujarat Themis Biosyn Ltd 路 Annual General Meeting 路 22 Sept 2026, 2:24 am
Gujarat Themis Biosyn Amends Preferential Issue to Raise Rs 335 Crore Gujarat Themis Biosyn issued an AGM notice corrigendum updating its preferential issue to up to 82,92,081 equity shares (FV Re 1) at Rs 404 per share, raising Rs 335.00 crore. Proceeds will fund the 100% equity acquisition of MicroBiopharm Japan Co., Ltd., including NCD redemption or debt repayment of Rs 310.00 crore, alongside Rs 25.00 crore for general corporate purposes within 12 months. Promoter entity Pharmaceutical Business Group (India) Limited will subscribe to 61,88,121 shares (Rs 250.00 crore), increasing total promoter holding from 59.33% to 60.25% post-issue.
Original exchange filing (PDF)
More announcements from Gujarat Themis Biosyn Ltd
- Recording of Analysts Meet held on 16.11.2026 路 17 Nov 2026
- Please refer to the attached Analysts Presentation 路 16 Nov 2026
- Please refer to the attachment 路 16 Nov 2026
- Please refer to the intimation of resignation of Company Secretary & Compliance Officer. 路 15 Nov 2026
- Please refer to the attachment 路 14 Nov 2026
- Kindly refer to the Un-audited Standalone & Consolidated Financial Results for the quarter and half year ended 30.09.2026 路 14 Nov 2026
- Gujarat Themis Biosyn Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 14 Nov 2026
- Outcome of the Board Meeting held on 14.11.2026 路 14 Nov 2026
